Abstract: Enzyme inhibitors play a significant role in the drug discovery process. For instance, acetylcholinesterase (AChE) inhibitors have applications in curing Alzheimer's disease (AD), senile dementia, ataxia, myasthenia gravis, and Parkinson's disease. Glutathione S-transferase (GST) inhibitors have applications as adjuvants to overcome anticancer and antiparasitic drug resistance problems. Compounds inhibiting the activity of α-glucosidase are used to treat type 2 diabetes mellitus and obesity problems. This article describes the identification of natural products exhibiting AChE, GST, and α-glucosidase inhibitory activities from medicinally important plants. Additionally, structure-activity relationship (SAR) studies of these newly discovered enzyme inhibitors are also discussed.
INTRODUCTION
A growing number of compounds with promising biomedical activity are supplied by natural product chemistry. Recent estimates indicate that approximately 50 % of commercially available antitumor and anti-infective agents are of natural products origin, and 25 % of these pharmaceuticals are of plant origin [1, 2] . The discovery of combinatorial chemistry two decades ago was thought to be a cost-effective method for providing lead compounds to the drug discovery process. Unfortunately, this branch of chemistry has failed to provide the structural diversity compared to natural product chemistry. Despite extensive research, combinatorial chemistry has yielded only one anticancer drug, sorafenib [3] , while almost half of the 877 small molecules introduced as pharmaceuticals between 1991 and 2002 are of natural products origin [4, 5] .
A key aspect of drug discovery is the identification of small molecules with enzyme-inhibiting activities. Enzymes are essential to human life, mediating biochemical processes including metabolism, cellular signal transduction, cell cycling, and development. Malfunction in these biochemical systems often leads to disease, the root cause of which can often be traced to the dysfunction, overexpression, or hyperactivation of the enzymes involved [6] . An understanding of diseases at the molecular level has led to the discovery of effective enzyme inhibitors that are used in clinical practice. Two such inhibitors are the cholesterol-lowering agent lovastatin (mevinolin) and the acetylcholinesterase (AChE) inhibitor galanthamine. Lovastatin acts at a key step in cholesterol biosynthesis, inhibiting the enzyme (3S)-hydroxy methylglutaryl-coenzyme A (HMG-CoA) reductase and preventing catalysis of the reduc-
GLUTATHIONE S-TRANSFERASE INHIBITORS
Presently, a lot of research is underway to explain the mechanisms of acquired drug resistance during the treatment of cancer and parasitic diseases. The cystosolic detoxification enzyme, GST (E.C. 2.1.5.18), has been suggested to play an active role in this process [22] . GSTs are phase II detoxification isozymes that catalyze the reaction of various exogenous and endogenous electrophilic substances with glutathione to make adduct. Glutathione adducts are soluble in water and therefore can easily be excreted from the body [23] . Anticancer drugs with electrophilic centers can easily form this adduct in the presence of GST and can be excreted from the body, thus lowering the efficiency of these chemotherapeutic agents. In humans, GSTs exist in the form of various dimerized isoenzyme classes: α (A), μ (M), ω, π (P), θ (T), ζ (Z), and σ classes. Their existence in different forms has provided broad substrate specificities promoting detoxification of many toxic substances. Overexpression of GST in various human cancers was discovered compared to the normal tissues [24] . A 2-fold increase in GST activity has been reported in the literature in lymphocytes obtained from chronic lymphocytic leukemia (CLL) patients, resistant to chlorambucil when compared with untreated CLL patients. The effectiveness of cancer chemotherapeutic agents might be improved by the use of GST inhibitors as adjuvant during cancer chemotherapy. Toward this end, we screened several medicinally important plants in GST inhibition assay and discovered that the crude methanolic extracts of Barleria prionitis, Nauclea latifolia, and Artocarpus nobilis exhibited anti-GST activity with IC 50 values of 160.0, 10.5, and 125 μg/ml, respectively. Phytochemical studies on Barleria prionitis yielded a new natural product, barlerinoside 7, exhibiting GST inhibitory activity with an IC 50 value of 12.4 μM. This bioactivity is more or less comparable with the GST inhibitory activity of a positive control, ethacrynic acid, a substrate GST inhibitor (IC 50 = 16.5 μM). Compound 7 has also shown free radical scavenging activity with an IC 50 value of 0.42 μg/ml [25] . Our chemical studies on the crude ethanolic extract of Nauclea latifolia yielded five known compounds, strictosamide 8, naucleamides A 9, naucleamide F 10, quinovic acid-3-O-β-rhamnosylpyranoside 11, and quinovic acid 3-O-β-fucosylpyranoside 12. Compounds 8-12 showed GST inhibitory activity with IC 50 values of 20.3, 37.3, 23.6, 143.8, and 53.5, respectively. Compound 8 showed significant anti-GST property and was isolated in a large quantity. It was, therefore, decided to carry out microbial reactions on this compound to prepare analogues and to evaluate them for GST inhibitory activity in order to study their SAR. To achieve this goal, we screened five different fungi, namely, Mucor plumbeus (ATCC 4740), Cunninghamella blakesleeana (ATCC 9245), C. echinulata (ATCC 9244), Curvularia lunata (ATCC 12017), Rhizopus circinans (ATCC 1225), and Aspergillus niger (ATCC 1004) for their capability to metabolize compound 8. During these biotransformation experiments, we discovered that C. blakesleeana and R. circinans metabolized compound 8 into 10-hydroxystrictosamide (13), 10-β-glucosyloxyvincoside lactam (14) , and 16,17-dihydro-10-β-glucosyloxyvincoside lactam (15) . C. blakesleeana is reported to perform hydroxylation reactions on aromatic compounds while R. circinans was discovered for the first time to perform this reaction [26] . In order to determine the sequence for the formation of metabolites 13-15, the time-dependent biotransformation experiments were also performed. These experiments were carried out by incubating compound 13 in the liquid culture of R. circinans; this afforded compounds 14 and 15. We incubated compound 14 in the liquid culture of this fungus to get compound 15. These results indicated that R. circinans initially performed microbial hydroxylation at C-10 of compound 8 to yield compound 13. This metabolite further underwent glycosylation, followed by reduction of the Δ 16-17 double bond to give compounds 14 and 15, respectively.
Compounds 13-15 were also evaluated for anti-GST assay and found to exhibit anti-GST activity with IC 50 values of 18.6, 12.3, and 46.6 μM, respectively [27] . Compounds 13 and 14 were found to be more potent compared to 8 (parent compound), and this might be possibly due to the introduction of polar groups that may have increased their solubility in water. Structures of compounds 7-15 are shown in Fig. 2 . [28] . These bioactivity data indicated that compounds 16-20 are more potent GST inhibitors than ethacrynic acid. The structures of compounds 7, 8, 10, 13, 14, and 16-20 all feature α,β-unsaturated carbonyl functionality, which suggests that this may constitute a pharmacophore for this expression of bioactivity. This was further confirmed by a significant decrease in the bioactivity of compound 15 (IC 50 = 46.6 μM), in which a double bond adjacent to the carbonyl group was reduced by microbial reaction. The α,β-unsaturated carbonyl group would lead to the formation of a glutathione adduct of these compounds through Michael addition to inhibit the activity of GST [29] . Structures of compounds 16-20 are shown in Fig. 3 . 
␣-GLUCOSIDASE INHIBITORS
α-Glucosidase is a membrane-bound enzyme that lies on the intestinal cells and catalyzes the final step of carbohydrate digestion to liberate free glucose, causing postprandial hyperglycemia [30] . This causes type 2 diabetes mellitus and affects approximately 2115 million people worldwide. The potent α-glucosidase inhibitors can be used to overcome this problem and to treat obese patient [31] . These compounds are also useful as antiviral, antimetastatic, immunomodulatory agents [32] . In this context, our recent phytochemical studies on the methanolic extract of Drypetes gossweileri afforded natural products displaying α-glucosidase inhibitory activity. observed that antifungal and α-glucosidase inhibition activities of compound 31 was significantly improved by the introduction of C-12α/NH 2 and C-13β/OH groups as these groups might be playing a role in binding with their target receptors through hydrogen bonding. These studies suggest that it is worthwhile to study the SAR on moderately bioactive natural products to improve their bioactivities. Structures of compounds 21-32 are presented in Fig. 4 .
CONCLUSION
In summary, our phytochemical studies on medicinally important plants have resulted in the identification of lead bioactive compounds exhibiting AChE, GST, and α-glucosidase inhibitory activities. For instance, compound 3 is identified as a potent AChE inhibitor while compounds 7, 8, and 16-20 have shown their potential as GST inhibitors whereas synthetic compound 31 exhibited the potent α-glucosidase inhibition and antifungal activities. The bioactivity data of 7, 8, and 13-20 suggested that an α,β-unsaturated carbonyl group may be acting as a pharmacophore the expression of GST inhibitory activity. Furthermore, compounds 16-20 were found to be more potent in vitro GST inhibitors than the currently used GST inhibitor, ethacrynic acid. These compounds need to be screened for in vivo GST inhibition activity. SAR studies on compound 27 warrant SAR studies on moderately active natural products to improve their bioactivities.
